Global Opioids Drug Market Growth 2026-2032
The global Opioids Drug market size is predicted to grow from US$ 9330 million in 2025 to US$ 8197 million in 2032; it is expected to grow at a CAGR of -1.9% from 2026 to 2032.
Opioid drugs are prescription medicines that act on mu, kappa, delta, and other opioid receptors in the central and peripheral nervous systems to produce analgesia, sedation, cough suppression, or relief from opioid withdrawal symptoms. Based on their origin and chemical structure, they can be classified as natural opiates, semi-synthetic opioids derived from opium alkaloids, and fully synthetic opioids. By clinical application, the category includes medicines for acute and chronic pain management, perioperative and anesthesia support, palliative care, and certain partial agonist or antagonist-containing therapies used to treat opioid use disorder. Major dosage forms include immediate- and extended-release oral formulations, injectable products, transdermal patches, transmucosal formulations, and long-acting injections. Opioids provide clinically important and sometimes difficult-to-replace therapeutic benefits, but they may also cause tolerance, physical dependence, addiction, respiratory depression, and overdose. Their development, manufacturing, distribution, prescribing, administration, and disposal are therefore subject to extensive regulatory controls.In 2025, global Opioid drugs production reached approximately 9500 million units.The average gross profit margin of this product is 75%.
Growth in surgical procedures, cancer and severe-trauma treatment, population aging, and the development of palliative care continue to support legitimate hospital demand for potent opioid analgesics and anesthesia-related products. In severe acute pain, cancer pain, end-of-life care, and selected complex perioperative settings, opioids retain advantages such as rapid onset, strong analgesic efficacy, and extensive clinical experience. Market development is increasingly centered on improving treatment precision and safety rather than expanding overall exposure. Relevant innovation areas include readily titratable short-acting products, extended-release formulations designed to reduce misuse, prefilled or ready-to-use injectables, and more reliable hospital supply systems. At the same time, opioid use disorder is increasingly managed as a chronic medical condition, creating a distinct and specialized market for long-acting buprenorphine, combination therapies, and treatment options capable of improving adherence and continuity of care.
The central challenge for the opioid industry is balancing clinical benefit with substantial public-health risk. Prolonged or inappropriate use may lead to tolerance, physical dependence, addiction, respiratory depression, misuse, and overdose, prompting regulators to strengthen prescribing information, risk education, product tracking, unused-drug disposal, and patient monitoring. Tighter prescribing practices and the development of non-opioid analgesics are reducing opioid use in some routine pain indications. Manufacturers also face controlled-substance quotas, approved sourcing requirements, strict inventory controls, secure transportation, diversion-prevention obligations, and extensive recordkeeping. Historical litigation, reputational exposure, and potential settlement liabilities may create lasting financial and brand-related consequences. Although illicit fentanyl is distinct from properly manufactured and prescribed pharmaceutical opioids, the broader social crisis can negatively affect public perceptions of the entire drug class and increase uncertainty in the regulatory and commercial environment.
Hospitals, surgical centers, oncology institutions, pain clinics, and palliative-care providers will remain the principal end users of pharmaceutical opioids. Procurement decisions, however, are shifting beyond efficacy and price toward supply reliability, convenient dosage forms, dosing flexibility, and risk-management capabilities. Acute-pain treatment increasingly emphasizes the shortest necessary treatment duration and multimodal analgesia, with opioids used alongside non-opioid analgesics, regional anesthesia, and other supportive therapies. Use in chronic non-cancer pain is expected to remain cautious, while cancer pain, critical care, severe trauma, and end-of-life treatment retain stronger clinical necessity. Treatment for opioid use disorder is progressing toward longer-acting, outpatient-based, and continuous-care models, supporting demand for extended-release injectables, buprenorphine-based medicines, and the complementary supply of naloxone. Future product competition will increasingly focus on differentiated delivery systems, safer administration, misuse reduction, dependable supply, and demonstrable real-world clinical value.
LP Information, Inc. (LPI) ' newest research report, the “Opioids Drug Industry Forecast” looks at past sales and reviews total world Opioids Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Opioids Drug sales for 2026 through 2032. With Opioids Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Opioids Drug industry.
This Insight Report provides a comprehensive analysis of the global Opioids Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Opioids Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Opioids Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Opioids Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Opioids Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioids Drug market by product type, application, key manufacturers and key regions and countries.
Opioid drugs are prescription medicines that act on mu, kappa, delta, and other opioid receptors in the central and peripheral nervous systems to produce analgesia, sedation, cough suppression, or relief from opioid withdrawal symptoms. Based on their origin and chemical structure, they can be classified as natural opiates, semi-synthetic opioids derived from opium alkaloids, and fully synthetic opioids. By clinical application, the category includes medicines for acute and chronic pain management, perioperative and anesthesia support, palliative care, and certain partial agonist or antagonist-containing therapies used to treat opioid use disorder. Major dosage forms include immediate- and extended-release oral formulations, injectable products, transdermal patches, transmucosal formulations, and long-acting injections. Opioids provide clinically important and sometimes difficult-to-replace therapeutic benefits, but they may also cause tolerance, physical dependence, addiction, respiratory depression, and overdose. Their development, manufacturing, distribution, prescribing, administration, and disposal are therefore subject to extensive regulatory controls.In 2025, global Opioid drugs production reached approximately 9500 million units.The average gross profit margin of this product is 75%.
Growth in surgical procedures, cancer and severe-trauma treatment, population aging, and the development of palliative care continue to support legitimate hospital demand for potent opioid analgesics and anesthesia-related products. In severe acute pain, cancer pain, end-of-life care, and selected complex perioperative settings, opioids retain advantages such as rapid onset, strong analgesic efficacy, and extensive clinical experience. Market development is increasingly centered on improving treatment precision and safety rather than expanding overall exposure. Relevant innovation areas include readily titratable short-acting products, extended-release formulations designed to reduce misuse, prefilled or ready-to-use injectables, and more reliable hospital supply systems. At the same time, opioid use disorder is increasingly managed as a chronic medical condition, creating a distinct and specialized market for long-acting buprenorphine, combination therapies, and treatment options capable of improving adherence and continuity of care.
The central challenge for the opioid industry is balancing clinical benefit with substantial public-health risk. Prolonged or inappropriate use may lead to tolerance, physical dependence, addiction, respiratory depression, misuse, and overdose, prompting regulators to strengthen prescribing information, risk education, product tracking, unused-drug disposal, and patient monitoring. Tighter prescribing practices and the development of non-opioid analgesics are reducing opioid use in some routine pain indications. Manufacturers also face controlled-substance quotas, approved sourcing requirements, strict inventory controls, secure transportation, diversion-prevention obligations, and extensive recordkeeping. Historical litigation, reputational exposure, and potential settlement liabilities may create lasting financial and brand-related consequences. Although illicit fentanyl is distinct from properly manufactured and prescribed pharmaceutical opioids, the broader social crisis can negatively affect public perceptions of the entire drug class and increase uncertainty in the regulatory and commercial environment.
Hospitals, surgical centers, oncology institutions, pain clinics, and palliative-care providers will remain the principal end users of pharmaceutical opioids. Procurement decisions, however, are shifting beyond efficacy and price toward supply reliability, convenient dosage forms, dosing flexibility, and risk-management capabilities. Acute-pain treatment increasingly emphasizes the shortest necessary treatment duration and multimodal analgesia, with opioids used alongside non-opioid analgesics, regional anesthesia, and other supportive therapies. Use in chronic non-cancer pain is expected to remain cautious, while cancer pain, critical care, severe trauma, and end-of-life treatment retain stronger clinical necessity. Treatment for opioid use disorder is progressing toward longer-acting, outpatient-based, and continuous-care models, supporting demand for extended-release injectables, buprenorphine-based medicines, and the complementary supply of naloxone. Future product competition will increasingly focus on differentiated delivery systems, safer administration, misuse reduction, dependable supply, and demonstrable real-world clinical value.
LP Information, Inc. (LPI) ' newest research report, the “Opioids Drug Industry Forecast” looks at past sales and reviews total world Opioids Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Opioids Drug sales for 2026 through 2032. With Opioids Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Opioids Drug industry.
This Insight Report provides a comprehensive analysis of the global Opioids Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Opioids Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Opioids Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Opioids Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Opioids Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioids Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Oxycodone
- Hydromorphone
- Codeine
- Fentanyl
Segmentation by Clinical Use:
- Cancer Pain
- Postoperative Pain
- Chronic Severe Pain
- Other
Segmentation by Dosage Form:
- Immediate-release Tablet
- Controlled-release Tablet
- Injection
- Transdermal Patch
- Other
Segmentation by Application:
- Pain Relief
- Anesthesia
- Others
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Mallinckrodt Pharmaceuticals
- Purdue Pharma
- Johnson & Johnson Janssen
- Teva Pharmaceutical
- Hikma Pharmaceuticals
- Pfizer
- Indivior
- Mundipharma
- Yichang Humanwell
- Northeast Pharmaceutical
- Viatris
- Depomed
- Endo Pharmaceuticals
Key Questions Addressed in this Report
- What is the 10-year outlook for the global Opioids Drug market?
- What factors are driving Opioids Drug market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Opioids Drug market opportunities vary by end market size?
- How does Opioids Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Opioids Drug Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Opioids Drug by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Opioids Drug by Country/Region, 2021, 2025 & 2032
2.2 Opioids Drug Segment by Type
2.2.1 Oxycodone
2.2.2 Hydromorphone
2.2.3 Codeine
2.2.4 Fentanyl
2.2.5 Opioids Drug Sales by Type
2.2.5.1 Global Opioids Drug Sales Market Share by Type (2021-2026)
2.2.5.2 Global Opioids Drug Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Opioids Drug Sale Price by Type (2021-2026)
2.3 Opioids Drug Segment by Clinical Use
2.3.1 Cancer Pain
2.3.2 Postoperative Pain
2.3.3 Chronic Severe Pain
2.3.4 Other
2.3.5 Opioids Drug Sales by Clinical Use
2.3.5.1 Global Opioids Drug Sales Market Share by Clinical Use (2021-2026)
2.3.5.2 Global Opioids Drug Revenue and Market Share by Clinical Use (2021-2026)
2.3.5.3 Global Opioids Drug Sale Price by Clinical Use (2021-2026)
2.4 Opioids Drug Segment by Dosage Form
2.4.1 Immediate-release Tablet
2.4.2 Controlled-release Tablet
2.4.3 Injection
2.4.4 Transdermal Patch
2.4.5 Other
2.4.6 Opioids Drug Sales by Dosage Form
2.4.6.1 Global Opioids Drug Sales Market Share by Dosage Form (2021-2026)
2.4.6.2 Global Opioids Drug Revenue and Market Share by Dosage Form (2021-2026)
2.4.6.3 Global Opioids Drug Sale Price by Dosage Form (2021-2026)
2.5 Opioids Drug Segment by Application
2.5.1 Pain Relief
2.5.2 Anesthesia
2.5.3 Others
2.5.4 Opioids Drug Sales by Application
2.5.4.1 Global Opioids Drug Sale Market Share by Application (2021-2026)
2.5.4.2 Global Opioids Drug Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Opioids Drug Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Opioids Drug Breakdown Data by Company
3.1.1 Global Opioids Drug Annual Sales by Company (2021-2026)
3.1.2 Global Opioids Drug Sales Market Share by Company (2021-2026)
3.2 Global Opioids Drug Annual Revenue by Company (2021-2026)
3.2.1 Global Opioids Drug Revenue by Company (2021-2026)
3.2.2 Global Opioids Drug Revenue Market Share by Company (2021-2026)
3.3 Global Opioids Drug Sale Price by Company
3.4 Key Manufacturers Opioids Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Opioids Drug Product Location Distribution
3.4.2 Players Opioids Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR OPIOIDS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Opioids Drug Market Size by Geographic Region (2021-2026)
4.1.1 Global Opioids Drug Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Opioids Drug Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Opioids Drug Market Size by Country/Region (2021-2026)
4.2.1 Global Opioids Drug Annual Sales by Country/Region (2021-2026)
4.2.2 Global Opioids Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Opioids Drug Sales Growth
4.4 APAC Opioids Drug Sales Growth
4.5 Europe Opioids Drug Sales Growth
4.6 Middle East & Africa Opioids Drug Sales Growth
5 AMERICAS
5.1 Americas Opioids Drug Sales by Country
5.1.1 Americas Opioids Drug Sales by Country (2021-2026)
5.1.2 Americas Opioids Drug Revenue by Country (2021-2026)
5.2 Americas Opioids Drug Sales by Type (2021-2026)
5.3 Americas Opioids Drug Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Opioids Drug Sales by Region
6.1.1 APAC Opioids Drug Sales by Region (2021-2026)
6.1.2 APAC Opioids Drug Revenue by Region (2021-2026)
6.2 APAC Opioids Drug Sales by Type (2021-2026)
6.3 APAC Opioids Drug Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Opioids Drug by Country
7.1.1 Europe Opioids Drug Sales by Country (2021-2026)
7.1.2 Europe Opioids Drug Revenue by Country (2021-2026)
7.2 Europe Opioids Drug Sales by Type (2021-2026)
7.3 Europe Opioids Drug Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Opioids Drug by Country
8.1.1 Middle East & Africa Opioids Drug Sales by Country (2021-2026)
8.1.2 Middle East & Africa Opioids Drug Revenue by Country (2021-2026)
8.2 Middle East & Africa Opioids Drug Sales by Type (2021-2026)
8.3 Middle East & Africa Opioids Drug Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Opioids Drug
10.3 Manufacturing Process Analysis of Opioids Drug
10.4 Industry Chain Structure of Opioids Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Opioids Drug Distributors
11.3 Opioids Drug Customer
12 WORLD FORECAST REVIEW FOR OPIOIDS DRUG BY GEOGRAPHIC REGION
12.1 Global Opioids Drug Market Size Forecast by Region
12.1.1 Global Opioids Drug Forecast by Region (2027-2032)
12.1.2 Global Opioids Drug Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Opioids Drug Forecast by Type (2027-2032)
12.7 Global Opioids Drug Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Mallinckrodt Pharmaceuticals
13.1.1 Mallinckrodt Pharmaceuticals Company Information
13.1.2 Mallinckrodt Pharmaceuticals Opioids Drug Product Portfolios and Specifications
13.1.3 Mallinckrodt Pharmaceuticals Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Mallinckrodt Pharmaceuticals Main Business Overview
13.1.5 Mallinckrodt Pharmaceuticals Latest Developments
13.2 Purdue Pharma
13.2.1 Purdue Pharma Company Information
13.2.2 Purdue Pharma Opioids Drug Product Portfolios and Specifications
13.2.3 Purdue Pharma Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Purdue Pharma Main Business Overview
13.2.5 Purdue Pharma Latest Developments
13.3 Johnson & Johnson Janssen
13.3.1 Johnson & Johnson Janssen Company Information
13.3.2 Johnson & Johnson Janssen Opioids Drug Product Portfolios and Specifications
13.3.3 Johnson & Johnson Janssen Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Johnson & Johnson Janssen Main Business Overview
13.3.5 Johnson & Johnson Janssen Latest Developments
13.4 Teva Pharmaceutical
13.4.1 Teva Pharmaceutical Company Information
13.4.2 Teva Pharmaceutical Opioids Drug Product Portfolios and Specifications
13.4.3 Teva Pharmaceutical Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Teva Pharmaceutical Main Business Overview
13.4.5 Teva Pharmaceutical Latest Developments
13.5 Hikma Pharmaceuticals
13.5.1 Hikma Pharmaceuticals Company Information
13.5.2 Hikma Pharmaceuticals Opioids Drug Product Portfolios and Specifications
13.5.3 Hikma Pharmaceuticals Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Hikma Pharmaceuticals Main Business Overview
13.5.5 Hikma Pharmaceuticals Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Opioids Drug Product Portfolios and Specifications
13.6.3 Pfizer Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 Indivior
13.7.1 Indivior Company Information
13.7.2 Indivior Opioids Drug Product Portfolios and Specifications
13.7.3 Indivior Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Indivior Main Business Overview
13.7.5 Indivior Latest Developments
13.8 Mundipharma
13.8.1 Mundipharma Company Information
13.8.2 Mundipharma Opioids Drug Product Portfolios and Specifications
13.8.3 Mundipharma Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Mundipharma Main Business Overview
13.8.5 Mundipharma Latest Developments
13.9 Yichang Humanwell
13.9.1 Yichang Humanwell Company Information
13.9.2 Yichang Humanwell Opioids Drug Product Portfolios and Specifications
13.9.3 Yichang Humanwell Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Yichang Humanwell Main Business Overview
13.9.5 Yichang Humanwell Latest Developments
13.10 Northeast Pharmaceutical
13.10.1 Northeast Pharmaceutical Company Information
13.10.2 Northeast Pharmaceutical Opioids Drug Product Portfolios and Specifications
13.10.3 Northeast Pharmaceutical Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Northeast Pharmaceutical Main Business Overview
13.10.5 Northeast Pharmaceutical Latest Developments
13.11 Viatris
13.11.1 Viatris Company Information
13.11.2 Viatris Opioids Drug Product Portfolios and Specifications
13.11.3 Viatris Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Viatris Main Business Overview
13.11.5 Viatris Latest Developments
13.12 Depomed
13.12.1 Depomed Company Information
13.12.2 Depomed Opioids Drug Product Portfolios and Specifications
13.12.3 Depomed Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Depomed Main Business Overview
13.12.5 Depomed Latest Developments
13.13 Endo Pharmaceuticals
13.13.1 Endo Pharmaceuticals Company Information
13.13.2 Endo Pharmaceuticals Opioids Drug Product Portfolios and Specifications
13.13.3 Endo Pharmaceuticals Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Endo Pharmaceuticals Main Business Overview
13.13.5 Endo Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Opioids Drug Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Opioids Drug by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Opioids Drug by Country/Region, 2021, 2025 & 2032
2.2 Opioids Drug Segment by Type
2.2.1 Oxycodone
2.2.2 Hydromorphone
2.2.3 Codeine
2.2.4 Fentanyl
2.2.5 Opioids Drug Sales by Type
2.2.5.1 Global Opioids Drug Sales Market Share by Type (2021-2026)
2.2.5.2 Global Opioids Drug Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Opioids Drug Sale Price by Type (2021-2026)
2.3 Opioids Drug Segment by Clinical Use
2.3.1 Cancer Pain
2.3.2 Postoperative Pain
2.3.3 Chronic Severe Pain
2.3.4 Other
2.3.5 Opioids Drug Sales by Clinical Use
2.3.5.1 Global Opioids Drug Sales Market Share by Clinical Use (2021-2026)
2.3.5.2 Global Opioids Drug Revenue and Market Share by Clinical Use (2021-2026)
2.3.5.3 Global Opioids Drug Sale Price by Clinical Use (2021-2026)
2.4 Opioids Drug Segment by Dosage Form
2.4.1 Immediate-release Tablet
2.4.2 Controlled-release Tablet
2.4.3 Injection
2.4.4 Transdermal Patch
2.4.5 Other
2.4.6 Opioids Drug Sales by Dosage Form
2.4.6.1 Global Opioids Drug Sales Market Share by Dosage Form (2021-2026)
2.4.6.2 Global Opioids Drug Revenue and Market Share by Dosage Form (2021-2026)
2.4.6.3 Global Opioids Drug Sale Price by Dosage Form (2021-2026)
2.5 Opioids Drug Segment by Application
2.5.1 Pain Relief
2.5.2 Anesthesia
2.5.3 Others
2.5.4 Opioids Drug Sales by Application
2.5.4.1 Global Opioids Drug Sale Market Share by Application (2021-2026)
2.5.4.2 Global Opioids Drug Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Opioids Drug Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Opioids Drug Breakdown Data by Company
3.1.1 Global Opioids Drug Annual Sales by Company (2021-2026)
3.1.2 Global Opioids Drug Sales Market Share by Company (2021-2026)
3.2 Global Opioids Drug Annual Revenue by Company (2021-2026)
3.2.1 Global Opioids Drug Revenue by Company (2021-2026)
3.2.2 Global Opioids Drug Revenue Market Share by Company (2021-2026)
3.3 Global Opioids Drug Sale Price by Company
3.4 Key Manufacturers Opioids Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Opioids Drug Product Location Distribution
3.4.2 Players Opioids Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR OPIOIDS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Opioids Drug Market Size by Geographic Region (2021-2026)
4.1.1 Global Opioids Drug Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Opioids Drug Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Opioids Drug Market Size by Country/Region (2021-2026)
4.2.1 Global Opioids Drug Annual Sales by Country/Region (2021-2026)
4.2.2 Global Opioids Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Opioids Drug Sales Growth
4.4 APAC Opioids Drug Sales Growth
4.5 Europe Opioids Drug Sales Growth
4.6 Middle East & Africa Opioids Drug Sales Growth
5 AMERICAS
5.1 Americas Opioids Drug Sales by Country
5.1.1 Americas Opioids Drug Sales by Country (2021-2026)
5.1.2 Americas Opioids Drug Revenue by Country (2021-2026)
5.2 Americas Opioids Drug Sales by Type (2021-2026)
5.3 Americas Opioids Drug Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Opioids Drug Sales by Region
6.1.1 APAC Opioids Drug Sales by Region (2021-2026)
6.1.2 APAC Opioids Drug Revenue by Region (2021-2026)
6.2 APAC Opioids Drug Sales by Type (2021-2026)
6.3 APAC Opioids Drug Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Opioids Drug by Country
7.1.1 Europe Opioids Drug Sales by Country (2021-2026)
7.1.2 Europe Opioids Drug Revenue by Country (2021-2026)
7.2 Europe Opioids Drug Sales by Type (2021-2026)
7.3 Europe Opioids Drug Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Opioids Drug by Country
8.1.1 Middle East & Africa Opioids Drug Sales by Country (2021-2026)
8.1.2 Middle East & Africa Opioids Drug Revenue by Country (2021-2026)
8.2 Middle East & Africa Opioids Drug Sales by Type (2021-2026)
8.3 Middle East & Africa Opioids Drug Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Opioids Drug
10.3 Manufacturing Process Analysis of Opioids Drug
10.4 Industry Chain Structure of Opioids Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Opioids Drug Distributors
11.3 Opioids Drug Customer
12 WORLD FORECAST REVIEW FOR OPIOIDS DRUG BY GEOGRAPHIC REGION
12.1 Global Opioids Drug Market Size Forecast by Region
12.1.1 Global Opioids Drug Forecast by Region (2027-2032)
12.1.2 Global Opioids Drug Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Opioids Drug Forecast by Type (2027-2032)
12.7 Global Opioids Drug Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Mallinckrodt Pharmaceuticals
13.1.1 Mallinckrodt Pharmaceuticals Company Information
13.1.2 Mallinckrodt Pharmaceuticals Opioids Drug Product Portfolios and Specifications
13.1.3 Mallinckrodt Pharmaceuticals Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Mallinckrodt Pharmaceuticals Main Business Overview
13.1.5 Mallinckrodt Pharmaceuticals Latest Developments
13.2 Purdue Pharma
13.2.1 Purdue Pharma Company Information
13.2.2 Purdue Pharma Opioids Drug Product Portfolios and Specifications
13.2.3 Purdue Pharma Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Purdue Pharma Main Business Overview
13.2.5 Purdue Pharma Latest Developments
13.3 Johnson & Johnson Janssen
13.3.1 Johnson & Johnson Janssen Company Information
13.3.2 Johnson & Johnson Janssen Opioids Drug Product Portfolios and Specifications
13.3.3 Johnson & Johnson Janssen Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Johnson & Johnson Janssen Main Business Overview
13.3.5 Johnson & Johnson Janssen Latest Developments
13.4 Teva Pharmaceutical
13.4.1 Teva Pharmaceutical Company Information
13.4.2 Teva Pharmaceutical Opioids Drug Product Portfolios and Specifications
13.4.3 Teva Pharmaceutical Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Teva Pharmaceutical Main Business Overview
13.4.5 Teva Pharmaceutical Latest Developments
13.5 Hikma Pharmaceuticals
13.5.1 Hikma Pharmaceuticals Company Information
13.5.2 Hikma Pharmaceuticals Opioids Drug Product Portfolios and Specifications
13.5.3 Hikma Pharmaceuticals Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Hikma Pharmaceuticals Main Business Overview
13.5.5 Hikma Pharmaceuticals Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Opioids Drug Product Portfolios and Specifications
13.6.3 Pfizer Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 Indivior
13.7.1 Indivior Company Information
13.7.2 Indivior Opioids Drug Product Portfolios and Specifications
13.7.3 Indivior Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Indivior Main Business Overview
13.7.5 Indivior Latest Developments
13.8 Mundipharma
13.8.1 Mundipharma Company Information
13.8.2 Mundipharma Opioids Drug Product Portfolios and Specifications
13.8.3 Mundipharma Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Mundipharma Main Business Overview
13.8.5 Mundipharma Latest Developments
13.9 Yichang Humanwell
13.9.1 Yichang Humanwell Company Information
13.9.2 Yichang Humanwell Opioids Drug Product Portfolios and Specifications
13.9.3 Yichang Humanwell Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Yichang Humanwell Main Business Overview
13.9.5 Yichang Humanwell Latest Developments
13.10 Northeast Pharmaceutical
13.10.1 Northeast Pharmaceutical Company Information
13.10.2 Northeast Pharmaceutical Opioids Drug Product Portfolios and Specifications
13.10.3 Northeast Pharmaceutical Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Northeast Pharmaceutical Main Business Overview
13.10.5 Northeast Pharmaceutical Latest Developments
13.11 Viatris
13.11.1 Viatris Company Information
13.11.2 Viatris Opioids Drug Product Portfolios and Specifications
13.11.3 Viatris Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Viatris Main Business Overview
13.11.5 Viatris Latest Developments
13.12 Depomed
13.12.1 Depomed Company Information
13.12.2 Depomed Opioids Drug Product Portfolios and Specifications
13.12.3 Depomed Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Depomed Main Business Overview
13.12.5 Depomed Latest Developments
13.13 Endo Pharmaceuticals
13.13.1 Endo Pharmaceuticals Company Information
13.13.2 Endo Pharmaceuticals Opioids Drug Product Portfolios and Specifications
13.13.3 Endo Pharmaceuticals Opioids Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Endo Pharmaceuticals Main Business Overview
13.13.5 Endo Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Opioids Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Opioids Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oxycodone
Table 4. Major Players of Hydromorphone
Table 5. Major Players of Codeine
Table 6. Major Players of Fentanyl
Table 7. Global Opioids Drug Sales by Type (2021-2026) & (M Units)
Table 8. Global Opioids Drug Sales Market Share by Type (2021-2026)
Table 9. Global Opioids Drug Revenue by Type (2021-2026) & ($ million)
Table 10. Global Opioids Drug Revenue Market Share by Type (2021-2026)
Table 11. Global Opioids Drug Sale Price by Type (2021-2026) & (USD/Unit)
Table 12. Major Players of Cancer Pain
Table 13. Major Players of Postoperative Pain
Table 14. Major Players of Chronic Severe Pain
Table 15. Major Players of Other
Table 16. Global Opioids Drug Sales by Clinical Use (2021-2026) & (M Units)
Table 17. Global Opioids Drug Sales Market Share by Clinical Use (2021-2026)
Table 18. Global Opioids Drug Revenue by Clinical Use (2021-2026) & ($ million)
Table 19. Global Opioids Drug Revenue Market Share by Clinical Use (2021-2026)
Table 20. Global Opioids Drug Sale Price by Clinical Use (2021-2026) & (USD/Unit)
Table 21. Major Players of Immediate-release Tablet
Table 22. Major Players of Controlled-release Tablet
Table 23. Major Players of Injection
Table 24. Major Players of Transdermal Patch
Table 25. Major Players of Other
Table 26. Global Opioids Drug Sales by Dosage Form (2021-2026) & (M Units)
Table 27. Global Opioids Drug Sales Market Share by Dosage Form (2021-2026)
Table 28. Global Opioids Drug Revenue by Dosage Form (2021-2026) & ($ million)
Table 29. Global Opioids Drug Revenue Market Share by Dosage Form (2021-2026)
Table 30. Global Opioids Drug Sale Price by Dosage Form (2021-2026) & (USD/Unit)
Table 31. Global Opioids Drug Sale by Application (2021-2026) & (M Units)
Table 32. Global Opioids Drug Sale Market Share by Application (2021-2026)
Table 33. Global Opioids Drug Revenue by Application (2021-2026) & ($ million)
Table 34. Global Opioids Drug Revenue Market Share by Application (2021-2026)
Table 35. Global Opioids Drug Sale Price by Application (2021-2026) & (USD/Unit)
Table 36. Global Opioids Drug Sales by Company (2021-2026) & (M Units)
Table 37. Global Opioids Drug Sales Market Share by Company (2021-2026)
Table 38. Global Opioids Drug Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Opioids Drug Revenue Market Share by Company (2021-2026)
Table 40. Global Opioids Drug Sale Price by Company (2021-2026) & (USD/Unit)
Table 41. Key Manufacturers Opioids Drug Producing Area Distribution and Sales Area
Table 42. Players Opioids Drug Products Offered
Table 43. Opioids Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Opioids Drug Sales by Geographic Region (2021-2026) & (M Units)
Table 47. Global Opioids Drug Sales Market Share Geographic Region (2021-2026)
Table 48. Global Opioids Drug Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Opioids Drug Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Opioids Drug Sales by Country/Region (2021-2026) & (M Units)
Table 51. Global Opioids Drug Sales Market Share by Country/Region (2021-2026)
Table 52. Global Opioids Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Opioids Drug Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Opioids Drug Sales by Country (2021-2026) & (M Units)
Table 55. Americas Opioids Drug Sales Market Share by Country (2021-2026)
Table 56. Americas Opioids Drug Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Opioids Drug Sales by Type (2021-2026) & (M Units)
Table 58. Americas Opioids Drug Sales by Application (2021-2026) & (M Units)
Table 59. APAC Opioids Drug Sales by Region (2021-2026) & (M Units)
Table 60. APAC Opioids Drug Sales Market Share by Region (2021-2026)
Table 61. APAC Opioids Drug Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Opioids Drug Sales by Type (2021-2026) & (M Units)
Table 63. APAC Opioids Drug Sales by Application (2021-2026) & (M Units)
Table 64. Europe Opioids Drug Sales by Country (2021-2026) & (M Units)
Table 65. Europe Opioids Drug Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Opioids Drug Sales by Type (2021-2026) & (M Units)
Table 67. Europe Opioids Drug Sales by Application (2021-2026) & (M Units)
Table 68. Middle East & Africa Opioids Drug Sales by Country (2021-2026) & (M Units)
Table 69. Middle East & Africa Opioids Drug Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Opioids Drug Sales by Type (2021-2026) & (M Units)
Table 71. Middle East & Africa Opioids Drug Sales by Application (2021-2026) & (M Units)
Table 72. Key Market Drivers & Growth Opportunities of Opioids Drug
Table 73. Key Market Challenges & Risks of Opioids Drug
Table 74. Key Industry Trends of Opioids Drug
Table 75. Opioids Drug Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Opioids Drug Distributors List
Table 78. Opioids Drug Customer List
Table 79. Global Opioids Drug Sales Forecast by Region (2027-2032) & (M Units)
Table 80. Global Opioids Drug Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Opioids Drug Sales Forecast by Country (2027-2032) & (M Units)
Table 82. Americas Opioids Drug Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Opioids Drug Sales Forecast by Region (2027-2032) & (M Units)
Table 84. APAC Opioids Drug Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Opioids Drug Sales Forecast by Country (2027-2032) & (M Units)
Table 86. Europe Opioids Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Opioids Drug Sales Forecast by Country (2027-2032) & (M Units)
Table 88. Middle East & Africa Opioids Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Opioids Drug Sales Forecast by Type (2027-2032) & (M Units)
Table 90. Global Opioids Drug Revenue Forecast by Type (2027-2032) & ($ millions)
Table 91. Global Opioids Drug Sales Forecast by Application (2027-2032) & (M Units)
Table 92. Global Opioids Drug Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. Mallinckrodt Pharmaceuticals Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. Mallinckrodt Pharmaceuticals Opioids Drug Product Portfolios and Specifications
Table 95. Mallinckrodt Pharmaceuticals Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 96. Mallinckrodt Pharmaceuticals Main Business
Table 97. Mallinckrodt Pharmaceuticals Latest Developments
Table 98. Purdue Pharma Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Purdue Pharma Opioids Drug Product Portfolios and Specifications
Table 100. Purdue Pharma Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 101. Purdue Pharma Main Business
Table 102. Purdue Pharma Latest Developments
Table 103. Johnson & Johnson Janssen Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. Johnson & Johnson Janssen Opioids Drug Product Portfolios and Specifications
Table 105. Johnson & Johnson Janssen Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 106. Johnson & Johnson Janssen Main Business
Table 107. Johnson & Johnson Janssen Latest Developments
Table 108. Teva Pharmaceutical Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Teva Pharmaceutical Opioids Drug Product Portfolios and Specifications
Table 110. Teva Pharmaceutical Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 111. Teva Pharmaceutical Main Business
Table 112. Teva Pharmaceutical Latest Developments
Table 113. Hikma Pharmaceuticals Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Hikma Pharmaceuticals Opioids Drug Product Portfolios and Specifications
Table 115. Hikma Pharmaceuticals Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 116. Hikma Pharmaceuticals Main Business
Table 117. Hikma Pharmaceuticals Latest Developments
Table 118. Pfizer Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 119. Pfizer Opioids Drug Product Portfolios and Specifications
Table 120. Pfizer Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 121. Pfizer Main Business
Table 122. Pfizer Latest Developments
Table 123. Indivior Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 124. Indivior Opioids Drug Product Portfolios and Specifications
Table 125. Indivior Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 126. Indivior Main Business
Table 127. Indivior Latest Developments
Table 128. Mundipharma Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 129. Mundipharma Opioids Drug Product Portfolios and Specifications
Table 130. Mundipharma Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 131. Mundipharma Main Business
Table 132. Mundipharma Latest Developments
Table 133. Yichang Humanwell Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 134. Yichang Humanwell Opioids Drug Product Portfolios and Specifications
Table 135. Yichang Humanwell Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 136. Yichang Humanwell Main Business
Table 137. Yichang Humanwell Latest Developments
Table 138. Northeast Pharmaceutical Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 139. Northeast Pharmaceutical Opioids Drug Product Portfolios and Specifications
Table 140. Northeast Pharmaceutical Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 141. Northeast Pharmaceutical Main Business
Table 142. Northeast Pharmaceutical Latest Developments
Table 143. Viatris Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 144. Viatris Opioids Drug Product Portfolios and Specifications
Table 145. Viatris Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 146. Viatris Main Business
Table 147. Viatris Latest Developments
Table 148. Depomed Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 149. Depomed Opioids Drug Product Portfolios and Specifications
Table 150. Depomed Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 151. Depomed Main Business
Table 152. Depomed Latest Developments
Table 153. Endo Pharmaceuticals Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 154. Endo Pharmaceuticals Opioids Drug Product Portfolios and Specifications
Table 155. Endo Pharmaceuticals Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 156. Endo Pharmaceuticals Main Business
Table 157. Endo Pharmaceuticals Latest Developments
Table 1. Opioids Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Opioids Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oxycodone
Table 4. Major Players of Hydromorphone
Table 5. Major Players of Codeine
Table 6. Major Players of Fentanyl
Table 7. Global Opioids Drug Sales by Type (2021-2026) & (M Units)
Table 8. Global Opioids Drug Sales Market Share by Type (2021-2026)
Table 9. Global Opioids Drug Revenue by Type (2021-2026) & ($ million)
Table 10. Global Opioids Drug Revenue Market Share by Type (2021-2026)
Table 11. Global Opioids Drug Sale Price by Type (2021-2026) & (USD/Unit)
Table 12. Major Players of Cancer Pain
Table 13. Major Players of Postoperative Pain
Table 14. Major Players of Chronic Severe Pain
Table 15. Major Players of Other
Table 16. Global Opioids Drug Sales by Clinical Use (2021-2026) & (M Units)
Table 17. Global Opioids Drug Sales Market Share by Clinical Use (2021-2026)
Table 18. Global Opioids Drug Revenue by Clinical Use (2021-2026) & ($ million)
Table 19. Global Opioids Drug Revenue Market Share by Clinical Use (2021-2026)
Table 20. Global Opioids Drug Sale Price by Clinical Use (2021-2026) & (USD/Unit)
Table 21. Major Players of Immediate-release Tablet
Table 22. Major Players of Controlled-release Tablet
Table 23. Major Players of Injection
Table 24. Major Players of Transdermal Patch
Table 25. Major Players of Other
Table 26. Global Opioids Drug Sales by Dosage Form (2021-2026) & (M Units)
Table 27. Global Opioids Drug Sales Market Share by Dosage Form (2021-2026)
Table 28. Global Opioids Drug Revenue by Dosage Form (2021-2026) & ($ million)
Table 29. Global Opioids Drug Revenue Market Share by Dosage Form (2021-2026)
Table 30. Global Opioids Drug Sale Price by Dosage Form (2021-2026) & (USD/Unit)
Table 31. Global Opioids Drug Sale by Application (2021-2026) & (M Units)
Table 32. Global Opioids Drug Sale Market Share by Application (2021-2026)
Table 33. Global Opioids Drug Revenue by Application (2021-2026) & ($ million)
Table 34. Global Opioids Drug Revenue Market Share by Application (2021-2026)
Table 35. Global Opioids Drug Sale Price by Application (2021-2026) & (USD/Unit)
Table 36. Global Opioids Drug Sales by Company (2021-2026) & (M Units)
Table 37. Global Opioids Drug Sales Market Share by Company (2021-2026)
Table 38. Global Opioids Drug Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Opioids Drug Revenue Market Share by Company (2021-2026)
Table 40. Global Opioids Drug Sale Price by Company (2021-2026) & (USD/Unit)
Table 41. Key Manufacturers Opioids Drug Producing Area Distribution and Sales Area
Table 42. Players Opioids Drug Products Offered
Table 43. Opioids Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Opioids Drug Sales by Geographic Region (2021-2026) & (M Units)
Table 47. Global Opioids Drug Sales Market Share Geographic Region (2021-2026)
Table 48. Global Opioids Drug Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Opioids Drug Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Opioids Drug Sales by Country/Region (2021-2026) & (M Units)
Table 51. Global Opioids Drug Sales Market Share by Country/Region (2021-2026)
Table 52. Global Opioids Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Opioids Drug Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Opioids Drug Sales by Country (2021-2026) & (M Units)
Table 55. Americas Opioids Drug Sales Market Share by Country (2021-2026)
Table 56. Americas Opioids Drug Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Opioids Drug Sales by Type (2021-2026) & (M Units)
Table 58. Americas Opioids Drug Sales by Application (2021-2026) & (M Units)
Table 59. APAC Opioids Drug Sales by Region (2021-2026) & (M Units)
Table 60. APAC Opioids Drug Sales Market Share by Region (2021-2026)
Table 61. APAC Opioids Drug Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Opioids Drug Sales by Type (2021-2026) & (M Units)
Table 63. APAC Opioids Drug Sales by Application (2021-2026) & (M Units)
Table 64. Europe Opioids Drug Sales by Country (2021-2026) & (M Units)
Table 65. Europe Opioids Drug Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Opioids Drug Sales by Type (2021-2026) & (M Units)
Table 67. Europe Opioids Drug Sales by Application (2021-2026) & (M Units)
Table 68. Middle East & Africa Opioids Drug Sales by Country (2021-2026) & (M Units)
Table 69. Middle East & Africa Opioids Drug Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Opioids Drug Sales by Type (2021-2026) & (M Units)
Table 71. Middle East & Africa Opioids Drug Sales by Application (2021-2026) & (M Units)
Table 72. Key Market Drivers & Growth Opportunities of Opioids Drug
Table 73. Key Market Challenges & Risks of Opioids Drug
Table 74. Key Industry Trends of Opioids Drug
Table 75. Opioids Drug Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Opioids Drug Distributors List
Table 78. Opioids Drug Customer List
Table 79. Global Opioids Drug Sales Forecast by Region (2027-2032) & (M Units)
Table 80. Global Opioids Drug Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Opioids Drug Sales Forecast by Country (2027-2032) & (M Units)
Table 82. Americas Opioids Drug Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Opioids Drug Sales Forecast by Region (2027-2032) & (M Units)
Table 84. APAC Opioids Drug Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Opioids Drug Sales Forecast by Country (2027-2032) & (M Units)
Table 86. Europe Opioids Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Opioids Drug Sales Forecast by Country (2027-2032) & (M Units)
Table 88. Middle East & Africa Opioids Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Opioids Drug Sales Forecast by Type (2027-2032) & (M Units)
Table 90. Global Opioids Drug Revenue Forecast by Type (2027-2032) & ($ millions)
Table 91. Global Opioids Drug Sales Forecast by Application (2027-2032) & (M Units)
Table 92. Global Opioids Drug Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. Mallinckrodt Pharmaceuticals Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. Mallinckrodt Pharmaceuticals Opioids Drug Product Portfolios and Specifications
Table 95. Mallinckrodt Pharmaceuticals Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 96. Mallinckrodt Pharmaceuticals Main Business
Table 97. Mallinckrodt Pharmaceuticals Latest Developments
Table 98. Purdue Pharma Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Purdue Pharma Opioids Drug Product Portfolios and Specifications
Table 100. Purdue Pharma Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 101. Purdue Pharma Main Business
Table 102. Purdue Pharma Latest Developments
Table 103. Johnson & Johnson Janssen Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. Johnson & Johnson Janssen Opioids Drug Product Portfolios and Specifications
Table 105. Johnson & Johnson Janssen Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 106. Johnson & Johnson Janssen Main Business
Table 107. Johnson & Johnson Janssen Latest Developments
Table 108. Teva Pharmaceutical Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Teva Pharmaceutical Opioids Drug Product Portfolios and Specifications
Table 110. Teva Pharmaceutical Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 111. Teva Pharmaceutical Main Business
Table 112. Teva Pharmaceutical Latest Developments
Table 113. Hikma Pharmaceuticals Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Hikma Pharmaceuticals Opioids Drug Product Portfolios and Specifications
Table 115. Hikma Pharmaceuticals Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 116. Hikma Pharmaceuticals Main Business
Table 117. Hikma Pharmaceuticals Latest Developments
Table 118. Pfizer Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 119. Pfizer Opioids Drug Product Portfolios and Specifications
Table 120. Pfizer Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 121. Pfizer Main Business
Table 122. Pfizer Latest Developments
Table 123. Indivior Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 124. Indivior Opioids Drug Product Portfolios and Specifications
Table 125. Indivior Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 126. Indivior Main Business
Table 127. Indivior Latest Developments
Table 128. Mundipharma Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 129. Mundipharma Opioids Drug Product Portfolios and Specifications
Table 130. Mundipharma Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 131. Mundipharma Main Business
Table 132. Mundipharma Latest Developments
Table 133. Yichang Humanwell Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 134. Yichang Humanwell Opioids Drug Product Portfolios and Specifications
Table 135. Yichang Humanwell Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 136. Yichang Humanwell Main Business
Table 137. Yichang Humanwell Latest Developments
Table 138. Northeast Pharmaceutical Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 139. Northeast Pharmaceutical Opioids Drug Product Portfolios and Specifications
Table 140. Northeast Pharmaceutical Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 141. Northeast Pharmaceutical Main Business
Table 142. Northeast Pharmaceutical Latest Developments
Table 143. Viatris Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 144. Viatris Opioids Drug Product Portfolios and Specifications
Table 145. Viatris Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 146. Viatris Main Business
Table 147. Viatris Latest Developments
Table 148. Depomed Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 149. Depomed Opioids Drug Product Portfolios and Specifications
Table 150. Depomed Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 151. Depomed Main Business
Table 152. Depomed Latest Developments
Table 153. Endo Pharmaceuticals Basic Information, Opioids Drug Manufacturing Base, Sales Area and Its Competitors
Table 154. Endo Pharmaceuticals Opioids Drug Product Portfolios and Specifications
Table 155. Endo Pharmaceuticals Opioids Drug Sales (M Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 156. Endo Pharmaceuticals Main Business
Table 157. Endo Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Opioids Drug
Figure 2. Opioids Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Opioids Drug Sales Growth Rate 2021-2032 (M Units)
Figure 7. Global Opioids Drug Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Opioids Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Opioids Drug Sales Market Share by Country/Region (2025)
Figure 10. Opioids Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oxycodone
Figure 12. Product Picture of Hydromorphone
Figure 13. Product Picture of Codeine
Figure 14. Product Picture of Fentanyl
Figure 15. Global Opioids Drug Sales Market Share by Type in 2026
Figure 16. Global Opioids Drug Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Cancer Pain
Figure 18. Product Picture of Postoperative Pain
Figure 19. Product Picture of Chronic Severe Pain
Figure 20. Product Picture of Other
Figure 21. Global Opioids Drug Sales Market Share by Clinical Use in 2026
Figure 22. Global Opioids Drug Revenue Market Share by Clinical Use (2021-2026)
Figure 23. Product Picture of Immediate-release Tablet
Figure 24. Product Picture of Controlled-release Tablet
Figure 25. Product Picture of Injection
Figure 26. Product Picture of Transdermal Patch
Figure 27. Product Picture of Other
Figure 28. Global Opioids Drug Sales Market Share by Dosage Form in 2026
Figure 29. Global Opioids Drug Revenue Market Share by Dosage Form (2021-2026)
Figure 30. Opioids Drug Consumed in Pain Relief
Figure 31. Global Opioids Drug Market: Pain Relief (2021-2026) & (M Units)
Figure 32. Opioids Drug Consumed in Anesthesia
Figure 33. Global Opioids Drug Market: Anesthesia (2021-2026) & (M Units)
Figure 34. Opioids Drug Consumed in Others
Figure 35. Global Opioids Drug Market: Others (2021-2026) & (M Units)
Figure 36. Global Opioids Drug Sale Market Share by Application (2025)
Figure 37. Global Opioids Drug Revenue Market Share by Application in 2025
Figure 38. Opioids Drug Sales by Company in 2025 (M Units)
Figure 39. Global Opioids Drug Sales Market Share by Company in 2025
Figure 40. Opioids Drug Revenue by Company in 2025 ($ millions)
Figure 41. Global Opioids Drug Revenue Market Share by Company in 2025
Figure 42. Global Opioids Drug Sales Market Share by Geographic Region (2021-2026)
Figure 43. Global Opioids Drug Revenue Market Share by Geographic Region in 2025
Figure 44. Americas Opioids Drug Sales 2021-2026 (M Units)
Figure 45. Americas Opioids Drug Revenue 2021-2026 ($ millions)
Figure 46. APAC Opioids Drug Sales 2021-2026 (M Units)
Figure 47. APAC Opioids Drug Revenue 2021-2026 ($ millions)
Figure 48. Europe Opioids Drug Sales 2021-2026 (M Units)
Figure 49. Europe Opioids Drug Revenue 2021-2026 ($ millions)
Figure 50. Middle East & Africa Opioids Drug Sales 2021-2026 (M Units)
Figure 51. Middle East & Africa Opioids Drug Revenue 2021-2026 ($ millions)
Figure 52. Americas Opioids Drug Sales Market Share by Country in 2025
Figure 53. Americas Opioids Drug Revenue Market Share by Country (2021-2026)
Figure 54. Americas Opioids Drug Sales Market Share by Type (2021-2026)
Figure 55. Americas Opioids Drug Sales Market Share by Application (2021-2026)
Figure 56. United States Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 57. Canada Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 58. Mexico Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 59. Brazil Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 60. APAC Opioids Drug Sales Market Share by Region in 2025
Figure 61. APAC Opioids Drug Revenue Market Share by Region (2021-2026)
Figure 62. APAC Opioids Drug Sales Market Share by Type (2021-2026)
Figure 63. APAC Opioids Drug Sales Market Share by Application (2021-2026)
Figure 64. China Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 65. Japan Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 66. South Korea Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 67. Southeast Asia Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 68. India Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 69. Australia Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 70. China Taiwan Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 71. Europe Opioids Drug Sales Market Share by Country in 2025
Figure 72. Europe Opioids Drug Revenue Market Share by Country (2021-2026)
Figure 73. Europe Opioids Drug Sales Market Share by Type (2021-2026)
Figure 74. Europe Opioids Drug Sales Market Share by Application (2021-2026)
Figure 75. Germany Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 76. France Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 77. UK Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 78. Italy Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 79. Russia Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 80. Middle East & Africa Opioids Drug Sales Market Share by Country (2021-2026)
Figure 81. Middle East & Africa Opioids Drug Sales Market Share by Type (2021-2026)
Figure 82. Middle East & Africa Opioids Drug Sales Market Share by Application (2021-2026)
Figure 83. Egypt Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 84. South Africa Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 85. Israel Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 86. Turkey Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 87. GCC Countries Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 88. Manufacturing Cost Structure Analysis of Opioids Drug in 2026
Figure 89. Manufacturing Process Analysis of Opioids Drug
Figure 90. Industry Chain Structure of Opioids Drug
Figure 91. Channels of Distribution
Figure 92. Global Opioids Drug Sales Market Forecast by Region (2027-2032)
Figure 93. Global Opioids Drug Revenue Market Share Forecast by Region (2027-2032)
Figure 94. Global Opioids Drug Sales Market Share Forecast by Type (2027-2032)
Figure 95. Global Opioids Drug Revenue Market Share Forecast by Type (2027-2032)
Figure 96. Global Opioids Drug Sales Market Share Forecast by Application (2027-2032)
Figure 97. Global Opioids Drug Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Opioids Drug
Figure 2. Opioids Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Opioids Drug Sales Growth Rate 2021-2032 (M Units)
Figure 7. Global Opioids Drug Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Opioids Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Opioids Drug Sales Market Share by Country/Region (2025)
Figure 10. Opioids Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oxycodone
Figure 12. Product Picture of Hydromorphone
Figure 13. Product Picture of Codeine
Figure 14. Product Picture of Fentanyl
Figure 15. Global Opioids Drug Sales Market Share by Type in 2026
Figure 16. Global Opioids Drug Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Cancer Pain
Figure 18. Product Picture of Postoperative Pain
Figure 19. Product Picture of Chronic Severe Pain
Figure 20. Product Picture of Other
Figure 21. Global Opioids Drug Sales Market Share by Clinical Use in 2026
Figure 22. Global Opioids Drug Revenue Market Share by Clinical Use (2021-2026)
Figure 23. Product Picture of Immediate-release Tablet
Figure 24. Product Picture of Controlled-release Tablet
Figure 25. Product Picture of Injection
Figure 26. Product Picture of Transdermal Patch
Figure 27. Product Picture of Other
Figure 28. Global Opioids Drug Sales Market Share by Dosage Form in 2026
Figure 29. Global Opioids Drug Revenue Market Share by Dosage Form (2021-2026)
Figure 30. Opioids Drug Consumed in Pain Relief
Figure 31. Global Opioids Drug Market: Pain Relief (2021-2026) & (M Units)
Figure 32. Opioids Drug Consumed in Anesthesia
Figure 33. Global Opioids Drug Market: Anesthesia (2021-2026) & (M Units)
Figure 34. Opioids Drug Consumed in Others
Figure 35. Global Opioids Drug Market: Others (2021-2026) & (M Units)
Figure 36. Global Opioids Drug Sale Market Share by Application (2025)
Figure 37. Global Opioids Drug Revenue Market Share by Application in 2025
Figure 38. Opioids Drug Sales by Company in 2025 (M Units)
Figure 39. Global Opioids Drug Sales Market Share by Company in 2025
Figure 40. Opioids Drug Revenue by Company in 2025 ($ millions)
Figure 41. Global Opioids Drug Revenue Market Share by Company in 2025
Figure 42. Global Opioids Drug Sales Market Share by Geographic Region (2021-2026)
Figure 43. Global Opioids Drug Revenue Market Share by Geographic Region in 2025
Figure 44. Americas Opioids Drug Sales 2021-2026 (M Units)
Figure 45. Americas Opioids Drug Revenue 2021-2026 ($ millions)
Figure 46. APAC Opioids Drug Sales 2021-2026 (M Units)
Figure 47. APAC Opioids Drug Revenue 2021-2026 ($ millions)
Figure 48. Europe Opioids Drug Sales 2021-2026 (M Units)
Figure 49. Europe Opioids Drug Revenue 2021-2026 ($ millions)
Figure 50. Middle East & Africa Opioids Drug Sales 2021-2026 (M Units)
Figure 51. Middle East & Africa Opioids Drug Revenue 2021-2026 ($ millions)
Figure 52. Americas Opioids Drug Sales Market Share by Country in 2025
Figure 53. Americas Opioids Drug Revenue Market Share by Country (2021-2026)
Figure 54. Americas Opioids Drug Sales Market Share by Type (2021-2026)
Figure 55. Americas Opioids Drug Sales Market Share by Application (2021-2026)
Figure 56. United States Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 57. Canada Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 58. Mexico Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 59. Brazil Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 60. APAC Opioids Drug Sales Market Share by Region in 2025
Figure 61. APAC Opioids Drug Revenue Market Share by Region (2021-2026)
Figure 62. APAC Opioids Drug Sales Market Share by Type (2021-2026)
Figure 63. APAC Opioids Drug Sales Market Share by Application (2021-2026)
Figure 64. China Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 65. Japan Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 66. South Korea Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 67. Southeast Asia Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 68. India Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 69. Australia Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 70. China Taiwan Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 71. Europe Opioids Drug Sales Market Share by Country in 2025
Figure 72. Europe Opioids Drug Revenue Market Share by Country (2021-2026)
Figure 73. Europe Opioids Drug Sales Market Share by Type (2021-2026)
Figure 74. Europe Opioids Drug Sales Market Share by Application (2021-2026)
Figure 75. Germany Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 76. France Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 77. UK Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 78. Italy Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 79. Russia Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 80. Middle East & Africa Opioids Drug Sales Market Share by Country (2021-2026)
Figure 81. Middle East & Africa Opioids Drug Sales Market Share by Type (2021-2026)
Figure 82. Middle East & Africa Opioids Drug Sales Market Share by Application (2021-2026)
Figure 83. Egypt Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 84. South Africa Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 85. Israel Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 86. Turkey Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 87. GCC Countries Opioids Drug Revenue Growth 2021-2026 ($ millions)
Figure 88. Manufacturing Cost Structure Analysis of Opioids Drug in 2026
Figure 89. Manufacturing Process Analysis of Opioids Drug
Figure 90. Industry Chain Structure of Opioids Drug
Figure 91. Channels of Distribution
Figure 92. Global Opioids Drug Sales Market Forecast by Region (2027-2032)
Figure 93. Global Opioids Drug Revenue Market Share Forecast by Region (2027-2032)
Figure 94. Global Opioids Drug Sales Market Share Forecast by Type (2027-2032)
Figure 95. Global Opioids Drug Revenue Market Share Forecast by Type (2027-2032)
Figure 96. Global Opioids Drug Sales Market Share Forecast by Application (2027-2032)
Figure 97. Global Opioids Drug Revenue Market Share Forecast by Application (2027-2032)
